Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2014 to Q4 2025

Type / Class
Equity / Common Shares, no par value
Symbol
AUPH on Nasdaq
Shares outstanding
130,702,820
Price per share
$15.95
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
65,694,131
Total reported value
$725,976,226
% of total 13F portfolios
0%
Share change
+6,979,206
Value change
+$84,236,111
Number of holders
239
Price from insider filings
$15.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 7.3% $74,318,595 10,029,500 TANG CAPITAL MANAGEMENT, LLC 28 Feb 2025
ILJIN SNT Co., Ltd. 5% $80,186,180 6,535,141 Chin Kyu Huh 11 Aug 2025
ARMISTICE CAPITAL, LLC 4.5% $47,424,000 6,400,000 Armistice Capital, LLC 31 Dec 2024

As of 30 Sep 2025, 239 institutional investors reported holding 65,694,131 shares of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH). This represents 50% of the company’s total 130,702,820 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) together control 38% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 8.7% 11,329,500 +13% 4.8% $125,190,975
BlackRock, Inc. 5.7% 7,448,858 -3.2% 0% $82,309,882
NEA Management Company, LLC 3% 3,969,834 0% 2.4% $43,866,666
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.6% 3,374,021 +214% 0.02% $37,282,932
STATE STREET CORP 2.1% 2,693,755 -3.6% 0% $29,765,993
MORGAN STANLEY 1.5% 1,946,785 -19% 0% $21,511,978
VANGUARD GROUP INC 1.2% 1,557,509 -9.5% 0% $17,210,474
GEODE CAPITAL MANAGEMENT, LLC 1.1% 1,485,700 -5.8% 0% $16,414,435
MARSHALL WACE, LLP 1.1% 1,483,132 +1273% 0.02% $16,388,610
RENAISSANCE TECHNOLOGIES LLC 1.1% 1,449,600 +25% 0.02% $16,018,080
TWO SIGMA INVESTMENTS, LP 1% 1,341,067 +729% 0.02% $14,818,790
JACOBS LEVY EQUITY MANAGEMENT, INC 0.93% 1,219,451 +63% 0.05% $13,474,934
Qube Research & Technologies Ltd 0.88% 1,152,845 -7.2% 0.02% $12,738,937
JANUS HENDERSON GROUP PLC 0.8% 1,041,121 +370% 0.01% $11,504,388
D. E. Shaw & Co., Inc. 0.7% 909,922 +166% 0.01% $10,054,638
NORTHERN TRUST CORP 0.69% 896,447 -2.7% 0% $9,905,738
GOLDMAN SACHS GROUP INC 0.64% 842,027 +92% 0% $9,304,399
JUPITER ASSET MANAGEMENT LTD 0.63% 823,579 -12% 0.08% $9,100,548
Trexquant Investment LP 0.61% 801,083 +101% 0.09% $8,851,967
CITADEL ADVISORS LLC 0.54% 702,655 +497% 0.01% $7,764,338
JANE STREET GROUP, LLC 0.52% 677,253 +45% 0.01% $7,483,646
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 0.43% 565,956 0% 0.01% $6,253,814
Squarepoint Ops LLC 0.43% 555,697 +15% 0.01% $6,140,452
RICE HALL JAMES & ASSOCIATES, LLC 0.42% 542,555 -1.4% 0.33% $5,995,233
Connor, Clark & Lunn Investment Management Ltd. 0.41% 541,188 -17% 0.02% $5,980,127

Institutional Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 698,801 $11,060,691 -$51,059 $15.95 12
2025 Q3 65,694,131 $725,976,226 +$84,236,111 $11.05 239
2025 Q2 58,318,900 $494,168,918 -$31,810,458 $8.47 216
2025 Q1 62,001,205 $498,579,149 +$33,892,926 $8.04 210
2024 Q4 57,780,357 $518,852,903 +$4,183,961 $8.98 197
2024 Q3 57,604,037 $421,946,761 +$21,818,902 $7.33 181
2024 Q2 55,315,964 $315,802,169 +$5,657,348 $5.71 169
2024 Q1 54,554,575 $273,320,204 +$4,055,438 $5.01 173
2023 Q4 54,324 $488,373 -$135,724 $8.99 1
2023 Q3 50,166,444 $389,798,085 -$989,461 $7.77 191
2023 Q2 49,680,960 $481,189,878 -$2,673,332 $9.68 194
2023 Q1 49,979,189 $547,764,755 +$7,316,657 $10.96 180
2022 Q4 51,064,540 $220,587,513 -$24,329,723 $4.32 179
2022 Q3 49,923,681 $375,428,174 +$26,657,254 $7.52 170
2022 Q2 49,558,301 $497,961,421 +$69,942,734 $10.05 187
2022 Q1 41,645,578 $515,466,128 +$962,954 $12.38 172
2021 Q4 38,416,465 $878,873,396 -$112,542,287 $22.87 175
2021 Q3 43,037,913 $951,648,355 -$4,444,993 $22.13 156
2021 Q2 49,059,590 $636,339,753 -$41,949,670 $12.96 160
2021 Q1 52,136,420 $677,387,141 -$80,743,245 $12.98 161
2020 Q4 56,884,883 $786,691,344 -$113,523,101 $13.83 135
2020 Q3 64,687,908 $952,631,966 +$74,665,121 $14.73 141
2020 Q2 58,562,535 $952,052,331 -$25,079,798 $16.25 124
2020 Q1 60,238,937 $874,020,351 +$158,162,377 $14.51 120
2019 Q4 48,813,071 $988,964,610 +$508,002,488 $20.26 108
2019 Q3 25,465,823 $135,988,269 -$23,269,740 $5.34 66
2019 Q2 29,318,177 $192,904,937 -$3,020,237 $6.58 68
2019 Q1 29,618,999 $192,521,300 +$48,973,006 $6.50 73
2018 Q4 22,159,841 $151,113,000 +$5,113,205 $6.82 56
2018 Q3 21,407,925 $142,134,000 +$1,972,372 $6.64 57
2018 Q2 21,263,832 $119,720,000 -$2,398,432 $5.63 62
2018 Q1 21,711,137 $112,682,000 -$9,997,030 $5.19 59
2017 Q4 23,088,941 $104,601,000 -$3,682,023 $4.53 62
2017 Q3 23,419,585 $146,842,000 +$1,993,221 $6.27 57
2017 Q2 23,175,154 $142,270,000 -$6,910,156 $6.13 63
2017 Q1 23,367,213 $169,688,835 +$109,345,913 $7.34 69
2016 Q4 8,620,472 $18,103,000 +$8,662,470 $2.10 21
2016 Q3 4,238,270 $12,814,000 -$8,125,591 $3.01 14
2016 Q2 7,069,693 $20,089,000 +$875,446 $2.78 12
2016 Q1 6,743,443 $19,673,000 +$25,046 $2.92 16
2015 Q4 6,732,938 $16,753,741 -$1,105,855 $2.47 14
2015 Q3 7,110,273 $20,112,000 +$2,913,131 $2.84 11
2015 Q2 7,207,516 $21,700,000 -$251,387 $3.02 10
2015 Q1 6,099,928 $26,668,000 +$445,323 $4.37 9
2014 Q4 12,671 $47,000 +$1,000 $4.76 2
2014 Q3 6,016,277 $19,267,000 +$19,266,958 $3.20 8